(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 June 2009 (18.06.2009)

PCT

(10) International Publication Number
WO 2009/074793 A3

(51) International Patent Classification:
A61K 38/18 (2006.01) *A61P 17/02* (2006.01)

(21) International Application Number:
PCT/GB2008/004072

(22) International Filing Date:
11 December 2008 (11.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0724203.5 12 December 2007 (12.12.2007) GB

(71) Applicant *(for all designated States except US)*: **RENOVO LIMITED** [GB/GB]; Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FERGUSON, Mark, William, James** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **O'KANE, Sharon** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **MASON, Tracey** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **COOPER, Mark** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **OCCLESTON, Nick** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **FAIRLAMB, David** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB). **BUSH, James** [GB/GB]; Renovo Limited, Incubator Building, 48 Grafton Street, Manchester M13 9XX (GB).

(74) Agent: **ARMSTRONG, Iain, Cheshire**; Marks & Clerk LLP, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
25 March 2010

WO 2009/074793 A3

(54) Title: METHODS FOR THE INHIBITION OF SCARRING

(57) Abstract: The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350ng and 1000ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350ng and 1000ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.